next generation flow | International Myeloma Foundation

Prof. Jesus San Miguel speaking

Week in Review

September 3

European Multiple Myeloma Clinician Prof. Jesús San Miguel Shares His Perspective on Minimal Residual Disease Testing

patient and doctor consultation

Week in Review

August 3

Coming Soon: Next Generation Testing and Decision Making

2023 IMWG Summit

Week in Review

June 21

2023 Mid-Year Science Update: Entering a New Era of Myeloma Care

What is minimal residual disease (MRD)?

May 4

What is minimal residual disease (MRD)?

Are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease (MRD)?

January 19

Are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease (MRD)?

Dr. Noemi Puig on NGF vs Mass Spec

December 27

Clinical Impact of NGF in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess MRD in Newly Diagnosed Multiple Myeloma Pts Receiving Maintenance

Dr. Laura Notarfranchi on BloodFlow

December 26

Ultra-Sensitive Assessment of MRD in Peripheral Blood of Multiple Myeloma Patients Using Bloodflow

Researcher looks at a slide sample next to a microscope.

Week in Review

December 27

FDA Approvals and Prize-Winning Research Are Welcome Good News for Myeloma Patients

Week in Review

July 6

In the News: The Search to Achieve a Cure Is Never Easy

Overhead view of medical staff looking at an ipad

Week in Review

May 19

Myeloma News Roundup: ASCO Abstracts Released, China Meetings Succeed, and iStopMM Clinic Officially Opens

blood testing for MRD results

Week in Review

April 20

New Studies Examine the Use of Liquid Biopsies and the Possible Causes of Myeloma

Week in Review

April 6

PET/CT Scanning Comes of Age: New IMWG Guidelines Published

Subscribe to next generation flow

Give Where Most Needed